

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
SAMPLE	METHOD											
080 FIBRINOGEN			CLIA TEST ID #: 825		EVALUATION CRITERIA: TARGET VALUE 20 %							
2022-551	79	CS-2500	67	DADE		12	437.667	37.368	8.54	350.000	525.000	
2022-552	79	CS-2500	67	DADE		12	224.083	12.533	5.59	179.000	269.000	
2022-553	79	CS-2500	67	DADE		12	229.583	18.228	7.94	184.000	276.000	
2022-554	79	CS-2500	67	DADE		12	139.750	9.558	6.84	112.000	168.000	
2022-555	79	CS-2500	67	DADE		12	170.583	13.653	8.00	136.000	205.000	
081 PART.THROM. TIME-PTT			CLIA TEST ID #: 835		EVALUATION CRITERIA: TARGET VALUE 15 %							
2022-551	62	DADE SYS.	35	DADE ACTIN		55	24.689	0.915	3.71	21.000	28.400	
2022-551	65	DADE BFTII	35	DADE ACTIN		11	25.273	1.619	6.41	21.500	29.100	
2022-551	69	DIAG.STAGO	49	STA-PTT		17	30.388	1.381	4.54	25.800	34.900	
2022-551	73	ACL 8 TO E	56	PTT-HEMO		36	40.763	1.995	4.90	34.600	46.900	
2022-551	76	STAGO STAR	49	STA-PTT		25	28.696	1.307	4.56	24.400	33.000	
2022-551	79	CS-2500	35	DADE ACTIN		12	24.750	0.296	1.20	21.000	28.500	
2022-552	62	DADE SYS.	35	DADE ACTIN		55	34.125	1.319	3.86	29.000	39.200	
2022-552	65	DADE BFTII	35	DADE ACTIN		11	37.445	2.963	7.91	31.800	43.100	
2022-552	69	DIAG.STAGO	49	STA-PTT		17	38.544	1.171	3.04	32.800	44.300	
2022-552	73	ACL 8 TO E	56	PTT-HEMO		36	39.078	0.974	2.49	33.200	44.900	
2022-552	76	STAGO STAR	49	STA-PTT		25	37.338	1.194	3.20	31.700	42.900	
2022-552	79	CS-2500	35	DADE ACTIN		12	35.367	1.016	2.87	30.100	40.700	
2022-553	62	DADE SYS.	35	DADE ACTIN		55	40.163	2.150	5.35	34.100	46.200	
2022-553	65	DADE BFTII	35	DADE ACTIN		11	44.291	3.932	8.88	37.600	50.900	
2022-553	69	DIAG.STAGO	49	STA-PTT		17	47.256	1.539	3.26	40.200	54.300	
2022-553	73	ACL 8 TO E	56	PTT-HEMO		36	46.206	1.436	3.11	39.300	53.100	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY			SUB: 70 GENERAL			GRP: 140 COAGULATION (HEMAT.)					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-553	76	STAGO STAR	49	STA-PTT	25	45.812	2.808	6.13	38.900	52.700	
2022-553	79	CS-2500	35	DADE ACTIN	12	41.975	2.128	5.07	35.700	48.300	
081	PART.THROM. TIME-PTT		CLIA TEST ID #: 835		EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-554	62	DADE SYS.	35	DADE ACTIN	55	24.677	0.934	3.78	21.000	28.400	
2022-554	65	DADE BFTII	35	DADE ACTIN	11	25.764	2.739	10.63	21.900	29.600	
2022-554	69	DIAG.STAGO	49	STA-PTT	17	30.463	1.503	4.93	25.900	35.000	
2022-554	73	ACL 8 TO E	56	PTT-HEMO	36	31.261	1.147	3.67	26.600	36.000	
2022-554	76	STAGO STAR	49	STA-PTT	25	29.204	1.418	4.86	24.800	33.600	
2022-554	79	CS-2500	35	DADE ACTIN	12	25.742	0.538	2.09	21.900	29.600	
2022-555	62	DADE SYS.	35	DADE ACTIN	55	23.719	0.939	3.96	20.200	27.300	
2022-555	65	DADE BFTII	35	DADE ACTIN	11	24.145	2.446	10.13	20.500	27.800	
2022-555	69	DIAG.STAGO	49	STA-PTT	17	26.725	0.814	3.04	22.700	30.700	
2022-555	73	ACL 8 TO E	56	PTT-HEMO	36	30.580	1.122	3.67	26.000	35.200	
2022-555	76	STAGO STAR	49	STA-PTT	25	25.740	1.995	7.75	21.900	29.600	
2022-555	79	CS-2500	35	DADE ACTIN	12	24.367	0.639	2.62	20.700	28.000	
082	PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845								
2022-551	62	DADE SYS.	33	DADE INNOV	56	10.982	0.274	2.50	9.300	12.600	
2022-551	62	DADE SYS.	33	DADE INNOV	56	14.044	0.313	2.23	11.900	16.200	
2022-551	65	DADE BFTII	33	DADE INNOV	12	10.318	0.393	3.81	8.800	11.900	
2022-551	65	DADE BFTII	33	DADE INNOV	12	10.675	0.277	2.60	9.100	12.300	
2022-551	73	ACL 8 TO E	41	HEMOSIL RE	32	11.753	0.206	1.75	10.000	13.500	
2022-551	76	STAGO STAR	44	STA NEO CI	16	14.138	0.596	4.21	12.000	16.300	
2022-551	79	CS-2500	33	DADE INNOV	13	11.323	0.162	1.43	9.600	13.000	
2022-552	62	DADE SYS.	33	DADE INNOV	56	25.344	0.704	2.78	21.500	29.100	
2022-552	62	DADE SYS.	33	DADE INNOV	56	19.296	0.578	2.99	16.400	22.200	
2022-552	65	DADE BFTII	33	DADE INNOV	12	20.025	1.213	6.06	17.000	23.000	
2022-552	65	DADE BFTII	33	DADE INNOV	12	20.367	1.038	5.10	17.300	23.400	
2022-552	73	ACL 8 TO E	41	HEMOSIL RE	32	22.891	0.977	4.27	19.500	26.300	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-552	76 STAGO STAR	44	STA NEO CI	16	26.206	1.257	4.80	22.300	30.100		
2022-552	79 CS-2500	33	DADE INNOV	13	19.646	0.298	1.52	16.700	22.600		
082	PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845							EVALUATION CRITERIA: TARGET VALUE 15 %	
2022-553	62 DADE SYS.	33	DADE INNOV	56	35.111	1.024	2.92	29.800	40.400		
2022-553	62 DADE SYS.	33	DADE INNOV	56	26.404	0.955	3.62	22.400	30.400		
2022-553	65 DADE BFTII	33	DADE INNOV	12	29.255	1.239	4.24	24.900	33.600		
2022-553	65 DADE BFTII	33	DADE INNOV	12	28.000	0.911	3.25	23.800	32.200		
2022-553	73 ACL 8 TO E	41	HEMOSIL RE	32	32.922	1.822	5.53	28.000	37.900		
2022-553	76 STAGO STAR	44	STA NEO CI	16	36.175	2.369	6.55	30.700	41.600		
2022-553	79 CS-2500	33	DADE INNOV	13	26.462	0.541	2.05	22.500	30.400		
2022-554	62 DADE SYS.	33	DADE INNOV	56	12.057	0.445	3.69	10.200	13.900		
2022-554	62 DADE SYS.	33	DADE INNOV	56	14.811	0.438	2.96	12.600	17.000		
2022-554	65 DADE BFTII	33	DADE INNOV	12	11.125	0.286	2.57	9.500	12.800		
2022-554	65 DADE BFTII	33	DADE INNOV	12	11.717	0.869	7.41	10.000	13.500		
2022-554	73 ACL 8 TO E	41	HEMOSIL RE	32	13.090	0.339	2.59	11.100	15.100		
2022-554	76 STAGO STAR	44	STA NEO CI	16	14.469	0.926	6.40	12.300	16.600		
2022-554	79 CS-2500	33	DADE INNOV	13	12.469	0.230	1.84	10.600	14.300		
2022-555	62 DADE SYS.	33	DADE INNOV	56	13.778	0.469	3.40	11.700	15.800		
2022-555	62 DADE SYS.	33	DADE INNOV	56	11.005	0.405	3.68	9.400	12.700		
2022-555	65 DADE BFTII	33	DADE INNOV	12	10.845	0.743	6.85	9.200	12.500		
2022-555	65 DADE BFTII	33	DADE INNOV	12	10.525	0.646	6.13	8.900	12.100		
2022-555	73 ACL 8 TO E	41	HEMOSIL RE	32	11.969	0.451	3.77	10.200	13.800		
2022-555	76 STAGO STAR	44	STA NEO CI	16	13.363	0.599	4.48	11.400	15.400		
2022-555	79 CS-2500	33	DADE INNOV	13	11.446	0.363	3.17	9.700	13.200		

Participant Summary

MONTH 6 OF YEAR 2022

SPE: 20 HEMATOLOGY		SUB: 70 GENERAL			GRP: 100 HEMA. CELL IDENTIFI.						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
072 HEMA. CELL IDENTIFI.											
2022-501					001	001	013 - LYMPHOCYTE	887	1	873	0
2022-501					001	001	001 - BLAST	887	873	873	100
2022-501					001	001	014 - LYMPHOCYTE	887	13	873	0
2022-502					046	046	050 - OVALOCYTE	904	8	876	0
2022-502					046	046	048 - ERYTHROCYT	904	1	876	0
2022-502					046	046	044 - ERYTHROCYT	904	18	876	0
2022-502					046	046	046 - ERYTHROCYT	904	876	876	100
2022-502					046	046	052 - SPHEROCYTE	904	1	876	0
2022-503					003	003	013 - LYMPHOCYTE	887	1	878	0
2022-503					003	003	006 - SEGMENTED	887	3	878	0
2022-503					003	003	004 - METAMYELOLOC	887	4	878	0
2022-503					003	003	001 - BLAST	887	1	878	0
2022-503					003	003	003 - MYELOCYTE	887	878	878	100
2022-504					020	020	019 - PLATELETS,	889	7	880	0
2022-504					020	020	013 - LYMPHOCYTE	889	1	880	0
2022-504					020	020	020 - GIANT PLA	889	880	880	100
2022-504					020	020	069 - Prolymphoc	889	1	880	0
2022-505					011	011	011 - HYPERSEGME	887	887	887	100

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 137 RETICULOCYTE COUNT

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
149	RETICULOCYTE COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{GREATER}					
2022-531	7	M.B.MANUAL		17	10.000	4.446	44.46	0	23.300		
2022-531	9	M.B. RICCA		27	9.215	1.893	20.55	3.500	14.900		
2022-531	24	Unicel DxH		16	5.569	1.087	19.52	2.300	8.800		
2022-531	25	SYSMEX XN		25	3.216	0.621	19.30	1.400	5.100		
2022-532	7	M.B.MANUAL		17	4.865	1.984	40.78	0	10.800		
2022-532	9	M.B. RICCA		27	4.752	1.170	24.62	1.200	8.300		
2022-532	24	Unicel DxH		16	3.125	0.650	20.78	1.200	5.100		
2022-532	25	SYSMEX XN		25	2.380	0.422	17.75	1.100	3.600		
2022-533	7	M.B.MANUAL		17	9.088	2.882	31.71	0.400	17.700		
2022-533	9	M.B. RICCA		27	9.141	1.778	19.45	3.800	14.500		
2022-533	24	Unicel DxH		16	5.669	1.260	22.23	1.900	9.400		
2022-533	25	SYSMEX XN		25	3.216	0.692	21.52	1.100	5.300		
2022-534	7	M.B.MANUAL		17	1.406	0.390	27.76	0.200	2.600		
2022-534	9	M.B. RICCA		27	1.154	0.271	23.46	0.300	2.000		
2022-534	24	Unicel DxH		16	0.594	0.148	24.89	0.200	1.000		
2022-534	25	SYSMEX XN		25	0.908	0.084	9.30	0.700	1.200		
2022-535	7	M.B.MANUAL		17	5.359	2.059	38.43	0	11.500		
2022-535	9	M.B. RICCA		27	5.215	1.408	27.00	1.000	9.400		
2022-535	24	Unicel DxH		16	3.050	0.672	22.02	1.000	5.100		
2022-535	25	SYSMEX XN		25	2.432	0.400	16.44	1.200	3.600		

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
153	SED. RATE (ESR)	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 35 %	{GREATER}				
2022-541	4	SEDIPLAST		593	12.022	2.757	22.93	4.000	20.000	
2022-541	10	SEDI RATE		98	13.396	2.477	18.49	6.000	21.000	
2022-541	11	SEDIMAT-15		55	14.873	10.875	73.12	0	47.000	
2022-541	14	GLOBAL SC.		10	14.500	3.202	22.08	5.000	24.000	
2022-541	19	MINI CUBE		29	19.655	3.689	18.77	9.000	31.000	
2022-542	4	SEDIPLAST		593	69.143	10.973	15.87	36.000	102.000	
2022-542	10	SEDI RATE		98	69.082	11.194	16.20	35.000	103.000	
2022-542	11	SEDIMAT-15		55	135.115	8.409	6.22	88.000	182.000	
2022-542	14	GLOBAL SC.		10	77.100	12.645	16.40	39.000	115.000	
2022-542	19	MINI CUBE		29	110.793	28.037	25.31	27.000	195.000	
2022-543	4	SEDIPLAST		593	12.172	2.653	21.80	4.000	20.000	
2022-543	10	SEDI RATE		98	13.691	2.668	19.49	6.000	22.000	
2022-543	11	SEDIMAT-15		55	17.327	15.582	89.93	0	64.000	
2022-543	14	GLOBAL SC.		10	15.200	3.124	20.55	6.000	25.000	
2022-543	19	MINI CUBE		29	19.724	3.215	16.30	10.000	29.000	
2022-544	4	SEDIPLAST		593	12.403	2.840	22.89	4.000	21.000	
2022-544	10	SEDI RATE		98	13.542	2.441	18.02	6.000	21.000	
2022-544	11	SEDIMAT-15		55	17.109	13.267	77.55	0	57.000	
2022-544	14	GLOBAL SC.		10	15.000	2.933	19.55	6.000	24.000	
2022-544	19	MINI CUBE		29	19.429	2.352	12.10	12.000	26.000	
2022-545	4	SEDIPLAST		593	69.511	10.928	15.72	37.000	102.000	
2022-545	10	SEDI RATE		98	70.112	11.017	15.71	37.000	103.000	
2022-545	11	SEDIMAT-15		55	129.019	20.046	15.54	69.000	189.000	
2022-545	14	GLOBAL SC.		10	78.400	9.319	11.89	50.000	106.000	
2022-545	19	MINI CUBE		29	112.724	29.493	26.16	24.000	201.000	

Participant Summary
MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2022521x	1 SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	144	61.371	1.658	2.70	46.000	76.700
2022521x	1 SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	144	12.172	1.729	14.21	9.100	15.200
2022521x	1 SYSMEX CBC	3	MONOCYTE	25	XS SERIES	144	0.341	0.289	84.87	0	2.300
2022521x	1 SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	144	16.205	0.642	3.96	12.200	20.300
2022521x	1 SYSMEX CBC	5	BASOPHIL	25	XS SERIES	144	9.947	1.012	10.17	7.500	12.400
2022521x	2 ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	134	75.387	1.090	1.45	56.500	94.200
2022521x	2 ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	28	71.668	1.023	1.43	53.800	89.600
2022521x	2 ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	134	17.452	1.055	6.04	13.100	21.800
2022521x	2 ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	28	15.868	1.100	6.93	11.900	19.800
2022521x	2 ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	134	2.008	0.470	23.43	0.000	4.000
2022521x	2 ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	28	2.507	0.443	17.68	0.500	4.500
2022521x	2 ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	134	5.158	0.367	7.12	3.200	7.200
2022521x	2 ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	28	5.600	0.753	13.44	3.600	7.600
2022521x	2 ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	134	87.679	1.970	2.25	65.800	109.600
2022521x	2 ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	28	4.407	0.070	1.60	2.400	6.400
2022521x	3 ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	17	72.659	0.678	0.93	54.500	90.800
2022521x	3 ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	17	13.571	0.481	3.55	10.200	17.000
2022521x	3 ADVIA 120	3	MONOCYTE	9	ADVIA-120	17	7.876	0.260	3.30	5.900	9.900
2022521x	3 ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	17	3.918	0.499	12.72	1.900	5.900
2022521x	3 ADVIA 120	5	BASOPHIL	9	ADVIA-120	17	0.382	0.110	28.70	0	2.400
2022521x	3 ADVIA 120	6	LUC	9	ADVIA-120	16	1.875	0.225	12.00	0	3.900
2022521x	4 AB- CELL-D	1	NEUTROPHIL	8	CELL-DYN	126	49.689	1.514	3.05	37.300	62.100
2022521x	4 AB- CELL-D	2	LYMPHOCYTE	8	CELL-DYN	126	39.191	2.352	6.00	29.400	49.000
2022521x	4 AB- CELL-D	3	MONOCYTE	8	CELL-DYN	126	7.862	1.166	14.83	5.900	9.900
2022521x	4 AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	126	2.424	0.625	25.79	0.400	4.400
2022521x	4 AB- CELL-D	5	BASOPHIL	8	CELL-DYN	126	0.842	0.578	68.67	0	2.800
2022521x	5 BECTON D	1	NEUTROPHIL	29	B.C600,800	58	57.309	1.294	2.26	43.000	71.600
2022521x	5 BECTON D	2	LYMPHOCYTE	29	B.C600,800	57	24.602	2.346	9.54	18.500	30.800

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022521x	5	BECTON D	3	MONOCYTE	29	B.C600,800	57	9.673	1.188	12.28	7.300	12.100
2022521x	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	57	8.359	0.374	4.47	6.300	10.400
2022521x	5	BECTON D	5	BASOPHIL	29	B.C600,800	57	0.000	0.000	0.00	0	2.000
2022521x	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	48	49.681	0.931	1.87	37.300	62.100
2022521x	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	48	38.769	1.808	4.66	29.100	48.500
2022521x	6	MR Mindray	3	MONOCYTE	32	BC-5390	48	5.717	1.232	21.56	3.700	7.700
2022521x	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	48	5.553	0.508	9.14	3.600	7.600
2022521x	6	MR Mindray	5	BASOPHIL	32	BC-5390	48	30.219	0.400	1.32	22.700	37.800
2022521x	7	DXH	1	NEUTROPHIL	36	BC DXH 500	38	78.929	1.091	1.38	59.200	98.700
2022521x	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	38	12.426	0.997	8.02	9.300	15.500
2022521x	7	DXH	3	MONOCYTE	36	BC DXH 500	38	0.265	0.237	89.61	0	2.300
2022521x	7	DXH	4	EOSINOPHIL	36	BC DXH 500	38	8.161	0.456	5.59	6.100	10.200
2022521x	7	DXH	5	BASOPHIL	36	BC DXH 500	38	0.197	0.300	151.77	0	2.200
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022522x	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	144	53.305	1.792	3.36	40.000	66.600
2022522x	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	144	22.529	2.265	10.05	16.900	28.200
2022522x	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	144	2.149	0.334	15.52	0.100	4.100
2022522x	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	144	13.646	0.807	5.91	10.200	17.100
2022522x	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	144	8.404	0.851	10.13	6.300	10.500
2022522x	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	136	57.081	2.159	3.78	42.800	71.400
2022522x	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	28	56.085	1.363	2.43	42.100	70.100
2022522x	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	132	32.607	1.868	5.73	24.500	40.800
2022522x	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	28	29.733	1.589	5.35	22.300	37.200
2022522x	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	134	2.493	0.646	25.89	0.500	4.500
2022522x	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	28	3.279	0.535	16.33	1.300	5.300
2022522x	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	134	7.751	0.772	9.96	5.800	9.800
2022522x	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	28	7.636	0.649	8.50	5.600	9.600
2022522x	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	134	64.917	1.236	1.90	48.700	81.100
2022522x	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	28	3.264	0.048	1.47	1.300	5.300
2022522x	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	17	42.947	1.259	2.93	32.200	53.700
2022522x	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	17	35.406	0.981	2.77	26.600	44.300

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022522x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	17	14.288	1.024	7.17	10.700	17.900
2022522x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	17	2.706	0.526	19.45	0.700	4.700
2022522x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	17	0.612	0.168	27.40	0	2.600
2022522x	3	ADVIA 120	6 LUC	9	ADVIA-120	16	4.375	0.660	15.09	2.400	6.400
2022522x	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	126	67.901	1.314	1.94	50.900	84.900
2022522x	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	126	22.457	1.615	7.19	16.800	28.100
2022522x	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	126	5.222	0.674	12.90	3.200	7.200
2022522x	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	126	3.787	0.510	13.48	1.800	5.800
2022522x	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	125	0.584	0.405	69.43	0	2.600
2022522x	5	BECTON D	1 NEUTROPHIL	29	B.C600,800	57	61.550	1.128	1.83	46.200	76.900
2022522x	5	BECTON D	2 LYMPHOCYTE	29	B.C600,800	58	24.891	1.636	6.57	18.700	31.100
2022522x	5	BECTON D	3 MONOCYTE	29	B.C600,800	57	8.472	0.932	11.01	6.400	10.600
2022522x	5	BECTON D	4 EOSINOPHIL	29	B.C600,800	57	5.020	0.268	5.34	3.000	7.000
2022522x	5	BECTON D	5 BASOPHIL	29	B.C600,800	57	0.025	0.043	175.25	0	2.000
2022522x	6	MR Mindray	1 NEUTROPHIL	32	BC-5390	48	55.655	1.163	2.09	41.700	69.600
2022522x	6	MR Mindray	2 LYMPHOCYTE	32	BC-5390	48	29.441	1.771	6.01	22.100	36.800
2022522x	6	MR Mindray	3 MONOCYTE	32	BC-5390	48	6.396	1.203	18.81	4.400	8.400
2022522x	6	MR Mindray	4 EOSINOPHIL	32	BC-5390	49	8.133	1.311	16.12	6.100	10.200
2022522x	6	MR Mindray	5 BASOPHIL	32	BC-5390	47	30.079	0.300	1.00	22.600	37.600
2022522x	7	DXH	1 NEUTROPHIL	36	BC DXH 500	38	46.792	2.783	5.95	35.100	58.500
2022522x	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	38	39.911	2.942	7.37	29.900	49.900
2022522x	7	DXH	3 MONOCYTE	36	BC DXH 500	38	0.308	0.396	128.49	0	2.300
2022522x	7	DXH	4 EOSINOPHIL	36	BC DXH 500	38	12.611	1.320	10.46	9.500	15.800
2022522x	7	DXH	5 BASOPHIL	36	BC DXH 500	38	0.384	0.584	151.94	0	2.400
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022523x	1	SYSMEX CBC	1 NEUTROPHIL	25	XS SERIES	144	57.478	2.046	3.56	43.100	71.800
2022523x	1	SYSMEX CBC	2 LYMPHOCYTE	25	XS SERIES	144	17.300	2.430	14.05	13.000	21.600
2022523x	1	SYSMEX CBC	3 MONOCYTE	25	XS SERIES	144	1.381	0.371	26.90	0	3.400
2022523x	1	SYSMEX CBC	4 EOSINOPHIL	25	XS SERIES	143	14.679	0.679	4.62	11.000	18.300
2022523x	1	SYSMEX CBC	5 BASOPHIL	25	XS SERIES	145	9.126	0.777	8.51	6.800	11.400
2022523x	2	ACT PENTRA	1 NEUTROPHIL	15	COUL ACT 5	134	61.267	1.059	1.73	46.000	76.600

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2022523x	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	28	59.333	1.001	1.69	44.500	74.200
2022523x	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	134	33.408	1.075	3.22	25.100	41.800
2022523x	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	28	30.968	1.366	4.41	23.200	38.700
2022523x	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	134	1.688	0.390	23.13	0	3.700
2022523x	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	27	2.100	0.475	22.60	0.100	4.100
2022523x	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	133	3.611	0.307	8.51	1.600	5.600
2022523x	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	28	3.957	0.585	14.79	2.000	6.000
2022523x	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	135	69.734	2.422	3.47	52.300	87.200
2022523x	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	28	3.500	0.067	1.90	1.500	5.500
2022523x	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	17	61.159	0.827	1.35	45.900	76.400
2022523x	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	17	23.700	0.710	3.00	17.800	29.600
2022523x	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	17	7.182	0.469	6.53	5.200	9.200
2022523x	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	17	4.618	0.595	12.89	2.600	6.600
2022523x	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	17	0.512	0.157	30.63	0	2.500
2022523x	3	ADVIA 120	6	LUC	9	ADVIA-120	16	3.169	0.400	12.61	1.200	5.200
2022523x	4	AB- CELL-D	1	NEUTROPHIL	8	CELL-DYN	126	74.079	1.211	1.63	55.600	92.600
2022523x	4	AB- CELL-D	2	LYMPHOCYTE	8	CELL-DYN	126	17.629	1.404	7.96	13.200	22.000
2022523x	4	AB- CELL-D	3	MONOCYTE	8	CELL-DYN	126	3.513	1.093	31.12	1.500	5.500
2022523x	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	126	4.485	0.279	6.23	2.500	6.500
2022523x	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	124	0.230	0.207	89.87	0	2.200
2022523x	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	57	70.775	0.779	1.10	53.100	88.500
2022523x	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	57	16.864	0.856	5.07	12.600	21.100
2022523x	5	BECTON D	3	MONOCYTE	29	B.C600,800	58	8.426	0.656	7.78	6.300	10.500
2022523x	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	57	3.873	0.282	7.28	1.900	5.900
2022523x	5	BECTON D	5	BASOPHIL	29	B.C600,800	57	0.026	0.044	167.33	0	2.000
2022523x	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	48	56.079	0.876	1.56	42.100	70.100
2022523x	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	48	29.279	1.539	5.26	22.000	36.600
2022523x	6	MR Mindray	3	MONOCYTE	32	BC-5390	47	6.270	1.130	18.02	4.300	8.300
2022523x	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	48	8.377	0.439	5.24	6.300	10.500
2022523x	6	MR Mindray	5	BASOPHIL	32	BC-5390	48	30.126	0.275	0.91	22.600	37.700
2022523x	7	DXH	1	NEUTROPHIL	36	BC DXH 500	38	69.318	1.219	1.76	52.000	86.600

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2022523x	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	38	26.189	1.441	5.50	19.600	32.700			
2022523x	7 DXH	3 MONOCYTE	36 BC DXH 500	38	0.258	0.248	96.07	0	2.300			
2022523x	7 DXH	4 EOSINOPHIL	36 BC DXH 500	38	3.837	0.503	13.11	1.800	5.800			
2022523x	7 DXH	5 BASOPHIL	36 BC DXH 500	38	0.400	0.546	136.57	0	2.400			
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2022524x	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	144	56.844	2.133	3.75	42.600	71.100			
2022524x	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	144	18.063	2.500	13.84	13.500	22.600			
2022524x	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	145	1.335	0.421	31.56	0	3.300			
2022524x	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	143	14.596	0.675	4.63	10.900	18.200			
2022524x	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	144	9.159	0.710	7.75	6.900	11.400			
2022524x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	134	61.227	1.236	2.02	45.900	76.500			
2022524x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	28	59.281	0.876	1.48	44.500	74.100			
2022524x	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	134	33.525	1.229	3.67	25.100	41.900			
2022524x	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	28	31.089	1.070	3.44	23.300	38.900			
2022524x	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	134	1.678	0.412	24.58	0	3.700			
2022524x	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	28	2.104	0.362	17.21	0.100	4.100			
2022524x	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	134	3.549	0.346	9.74	1.500	5.500			
2022524x	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	27	3.963	0.671	16.92	2.000	6.000			
2022524x	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	134	69.456	2.023	2.91	52.100	86.800			
2022524x	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	29	3.511	0.101	2.88	1.500	5.500			
2022524x	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	17	60.918	0.646	1.06	45.700	76.100			
2022524x	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	17	23.829	0.456	1.91	17.900	29.800			
2022524x	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	7.406	0.413	5.58	5.400	9.400			
2022524x	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	17	4.513	0.330	7.30	2.500	6.500			
2022524x	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	17	0.518	0.146	28.30	0	2.500			
2022524x	3 ADVIA 120	6 LUC	9 ADVIA-120	16	2.925	0.413	14.12	0.900	4.900			
2022524x	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	126	76.955	0.895	1.16	57.700	96.200			
2022524x	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	126	13.534	0.962	7.10	10.200	16.900			
2022524x	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	126	4.204	0.593	14.10	2.200	6.200			
2022524x	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	126	4.946	0.314	6.35	2.900	6.900			
2022524x	4 AB- CELL-D	5 BASOPHIL	8 CELL-DYN	124	0.264	0.203	76.80	0	2.300			

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022524x	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	57	69.743	0.565	0.81	52.300	87.200
2022524x	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	57	18.523	0.815	4.40	13.900	23.200
2022524x	5	BECTON D	3	MONOCYTE	29	B.C600,800	57	7.758	0.604	7.79	5.800	9.800
2022524x	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	58	3.923	0.264	6.72	1.900	5.900
2022524x	5	BECTON D	5	BASOPHIL	29	B.C600,800	57	0.025	0.043	175.25	0	2.000
2022524x	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	48	62.555	1.033	1.65	46.900	78.200
2022524x	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	48	19.326	1.256	6.50	14.500	24.200
2022524x	6	MR Mindray	3	MONOCYTE	32	BC-5390	48	6.442	1.049	16.29	4.400	8.400
2022524x	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	48	11.615	0.451	3.89	8.700	14.500
2022524x	6	MR Mindray	5	BASOPHIL	32	BC-5390	48	31.583	0.160	0.51	23.700	39.500
2022524x	7	DXH	1	NEUTROPHIL	36	BC DXH 500	38	69.262	1.344	1.94	51.900	86.600
2022524x	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	38	26.137	1.467	5.61	19.600	32.700
2022524x	7	DXH	3	MONOCYTE	36	BC DXH 500	38	0.195	0.220	113.31	0	2.200
2022524x	7	DXH	4	EOSINOPHIL	36	BC DXH 500	38	3.935	0.469	11.91	1.900	5.900
2022524x	7	DXH	5	BASOPHIL	36	BC DXH 500	38	0.387	0.555	143.46	0	2.400
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022525x	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	144	61.069	1.454	2.38	45.800	76.300
2022525x	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	144	12.286	1.346	10.95	9.200	15.400
2022525x	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	143	0.319	0.270	84.50	0	2.300
2022525x	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	145	16.272	0.561	3.45	12.200	20.300
2022525x	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	144	10.056	1.055	10.49	7.500	12.600
2022525x	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	134	56.799	2.143	3.77	42.600	71.000
2022525x	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	28	55.726	1.914	3.44	41.800	69.700
2022525x	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	134	33.180	1.957	5.90	24.900	41.500
2022525x	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	28	30.382	2.222	7.31	22.800	38.000
2022525x	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	135	2.432	0.707	29.05	0.400	4.400
2022525x	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	28	3.419	0.532	15.56	1.400	5.400
2022525x	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	133	7.607	0.625	8.21	5.600	9.600
2022525x	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	28	7.486	0.699	9.34	5.500	9.500
2022525x	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	133	65.051	1.238	1.90	48.800	81.300
2022525x	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	28	3.257	0.062	1.91	1.300	5.300

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022525x	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	18	42.776	2.382	5.57	32.100	53.500
2022525x	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	18	34.876	5.256	15.07	26.200	43.600
2022525x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	16	14.207	0.955	6.72	10.700	17.800
2022525x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	17	2.841	0.769	27.05	0.800	4.800
2022525x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	17	0.665	0.206	30.94	0	2.700
2022525x	3	ADVIA 120	6 LUC	9	ADVIA-120	16	4.373	0.566	12.95	2.400	6.400
2022525x	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	125	50.662	1.522	3.00	38.000	63.300
2022525x	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	126	38.018	2.148	5.65	28.500	47.500
2022525x	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	126	7.744	1.206	15.57	5.700	9.700
2022525x	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	126	2.580	0.619	23.99	0.600	4.600
2022525x	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	125	0.928	0.685	73.83	0	2.900
2022525x	5	BECTON D	1 NEUTROPHIL	29	B.C600,800	57	56.541	1.138	2.01	42.400	70.700
2022525x	5	BECTON D	2 LYMPHOCYTE	29	B.C600,800	57	25.988	2.049	7.88	19.500	32.500
2022525x	5	BECTON D	3 MONOCYTE	29	B.C600,800	57	9.204	1.051	11.42	6.900	11.500
2022525x	5	BECTON D	4 EOSINOPHIL	29	B.C600,800	56	8.311	0.398	4.79	6.200	10.400
2022525x	5	BECTON D	5 BASOPHIL	29	B.C600,800	59	0.003	0.018	529.15	0	2.000
2022525x	6	MR Mindray	1 NEUTROPHIL	32	BC-5390	48	49.809	1.033	2.07	37.400	62.300
2022525x	6	MR Mindray	2 LYMPHOCYTE	32	BC-5390	48	38.148	2.203	5.77	28.600	47.700
2022525x	6	MR Mindray	3 MONOCYTE	32	BC-5390	48	5.919	1.065	17.99	3.900	7.900
2022525x	6	MR Mindray	4 EOSINOPHIL	32	BC-5390	48	5.656	0.587	10.39	3.700	7.700
2022525x	6	MR Mindray	5 BASOPHIL	32	BC-5390	48	30.109	0.466	1.55	22.600	37.600
2022525x	7	DXH	1 NEUTROPHIL	36	BC DXH 500	39	46.405	3.068	6.61	34.800	58.000
2022525x	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	37	40.395	3.654	9.05	30.300	50.500
2022525x	7	DXH	3 MONOCYTE	36	BC DXH 500	38	0.167	0.264	158.11	0	2.200
2022525x	7	DXH	4 EOSINOPHIL	36	BC DXH 500	38	12.754	1.319	10.34	9.600	15.900
2022525x	7	DXH	5 BASOPHIL	36	BC DXH 500	38	0.208	0.431	207.02	0	2.200

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
185	Diff 6 Parameter Ins		CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE	25 %	OR 2.00	{GREATER}					
2022521y	1 6 PAR REG	1	NEUTROPHIL	31 SYSMEX XN	38	64.511	1.379	2.14	48.400	80.600		
2022521y	1 6 PAR REG	1	NEUTROPHIL	35 SYS XNL SR	76	62.612	1.216	1.94	47.000	78.300		
2022521y	1 6 PAR REG	2	LYMPHOCYTE	31 SYSMEX XN	38	13.846	1.497	10.81	10.400	17.300		
2022521y	1 6 PAR REG	2	LYMPHOCYTE	35 SYS XNL SR	76	10.633	0.938	8.82	8.000	13.300		
2022521y	1 6 PAR REG	3	MONOCYTE	31 SYSMEX XN	38	1.122	0.331	29.54	0	3.100		
2022521y	1 6 PAR REG	3	MONOCYTE	35 SYS XNL SR	76	0.646	0.305	47.29	0	2.600		
2022521y	1 6 PAR REG	4	EOSINOPHIL	31 SYSMEX XN	38	15.334	0.819	5.34	11.500	19.200		
2022521y	1 6 PAR REG	4	EOSINOPHIL	35 SYS XNL SR	76	16.203	1.132	6.99	12.200	20.300		
2022521y	1 6 PAR REG	5	BASOPHIL	31 SYSMEX XN	38	4.981	1.499	30.10	3.000	7.000		
2022521y	1 6 PAR REG	5	BASOPHIL	35 SYS XNL SR	76	9.797	0.875	8.93	7.300	12.200		
2022521y	1 6 PAR REG	6	IMMATURE G	31 SYSMEX XN	38	16.465	1.177	7.15	12.300	20.600		
2022521y	1 6 PAR REG	6	IMMATURE G	35 SYS XNL SR	76	17.646	1.310	7.43	13.200	22.100		
2022521y	1 6 PAR REG	7	NRBC	31 SYSMEX XN	21	0.000	0.000	0.00	0	2.000		
2022522y	1 6 PAR REG	1	NEUTROPHIL	31 SYSMEX XN	38	54.132	1.109	2.05	40.600	67.700		
2022522y	1 6 PAR REG	1	NEUTROPHIL	35 SYS XNL SR	76	51.414	1.386	2.70	38.600	64.300		
2022522y	1 6 PAR REG	2	LYMPHOCYTE	31 SYSMEX XN	38	23.859	0.999	4.18	17.900	29.800		
2022522y	1 6 PAR REG	2	LYMPHOCYTE	35 SYS XNL SR	76	25.372	1.674	6.60	19.000	31.700		
2022522y	1 6 PAR REG	3	MONOCYTE	31 SYSMEX XN	38	3.549	0.728	20.53	1.500	5.500		
2022522y	1 6 PAR REG	3	MONOCYTE	35 SYS XNL SR	76	1.747	0.338	19.33	0	3.700		
2022522y	1 6 PAR REG	4	EOSINOPHIL	31 SYSMEX XN	38	13.429	0.631	4.70	10.100	16.800		
2022522y	1 6 PAR REG	4	EOSINOPHIL	35 SYS XNL SR	76	13.477	0.772	5.73	10.100	16.800		
2022522y	1 6 PAR REG	5	BASOPHIL	31 SYSMEX XN	38	5.031	0.808	16.06	3.000	7.000		
2022522y	1 6 PAR REG	5	BASOPHIL	35 SYS XNL SR	76	8.057	0.866	10.75	6.000	10.100		
2022522y	1 6 PAR REG	6	IMMATURE G	31 SYSMEX XN	38	13.746	0.657	4.78	10.300	17.200		
2022522y	1 6 PAR REG	6	IMMATURE G	35 SYS XNL SR	76	13.991	0.832	5.95	10.500	17.500		
2022522y	1 6 PAR REG	7	NRBC	31 SYSMEX XN	21	0.000	0.000	0.00	0	2.000		
2022523y	1 6 PAR REG	1	NEUTROPHIL	31 SYSMEX XN	38	58.445	1.616	2.77	43.800	73.100		

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022523y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	76	55.466	1.182	2.13	41.600	69.300
2022523y	1	6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	38	19.368	1.175	6.07	14.500	24.200
2022523y	1	6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	76	20.251	1.364	6.74	15.200	25.300
2022523y	1	6 PAR REG	3	MONOCYTE	31	SYSMEX XN	38	2.370	0.570	24.04	0.400	4.400
2022523y	1	6 PAR REG	3	MONOCYTE	35	SYS XNL SR	76	0.949	0.631	66.49	0	2.900
2022523y	1	6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	38	14.722	0.528	3.58	11.000	18.400
2022523y	1	6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	76	14.777	0.589	3.99	11.100	18.500
2022523y	1	6 PAR REG	5	BASOPHIL	31	SYSMEX XN	38	5.047	0.970	19.21	3.000	7.000
2022523y	1	6 PAR REG	5	BASOPHIL	35	SYS XNL SR	75	8.533	0.867	10.16	6.400	10.700
2022523y	1	6 PAR REG	6	IMMATURE G	31	SYSMEX XN	38	14.516	0.589	4.06	10.900	18.100
2022523y	1	6 PAR REG	6	IMMATURE G	35	SYS XNL SR	76	14.932	0.789	5.28	11.200	18.700
2022523y	1	6 PAR REG	7	NRBC	31	SYSMEX XN	21	0.140	0.132	94.22	0	2.100
185 Diff 6 Parameter Ins			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022524y	1	6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	38	58.119	1.311	2.26	43.600	72.600
2022524y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	75	55.271	1.123	2.03	41.500	69.100
2022524y	1	6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	38	19.530	1.164	5.96	14.600	24.400
2022524y	1	6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	75	20.728	1.074	5.18	15.500	25.900
2022524y	1	6 PAR REG	3	MONOCYTE	31	SYSMEX XN	38	2.286	0.517	22.62	0.300	4.300
2022524y	1	6 PAR REG	3	MONOCYTE	35	SYS XNL SR	75	0.911	0.651	71.48	0	2.900
2022524y	1	6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	38	14.736	0.489	3.32	11.100	18.400
2022524y	1	6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	75	14.742	0.593	4.02	11.100	18.400
2022524y	1	6 PAR REG	5	BASOPHIL	31	SYSMEX XN	38	5.059	1.371	27.10	3.100	7.100
2022524y	1	6 PAR REG	5	BASOPHIL	35	SYS XNL SR	75	8.440	0.823	9.75	6.300	10.500
2022524y	1	6 PAR REG	6	IMMATURE G	31	SYSMEX XN	38	14.797	0.605	4.09	11.100	18.500
2022524y	1	6 PAR REG	6	IMMATURE G	35	SYS XNL SR	75	14.912	0.759	5.09	11.200	18.600
2022524y	1	6 PAR REG	7	NRBC	31	SYSMEX XN	21	0.135	0.106	78.65	0	2.100
2022525y	1	6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	38	64.008	1.103	1.72	48.000	80.000
2022525y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	76	62.745	1.369	2.18	47.100	78.400
2022525y	1	6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	38	13.916	1.299	9.34	10.400	17.400

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022525y	1	6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	76	10.627	1.034	9.73	8.000	13.300
2022525y	1	6 PAR REG	3	MONOCYTE	31	SYSMEX XN	38	1.214	0.367	30.24	0	3.200
2022525y	1	6 PAR REG	3	MONOCYTE	35	SYS XNL SR	76	0.636	0.292	45.95	0	2.600
2022525y	1	6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	38	15.641	0.811	5.18	11.700	19.600
2022525y	1	6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	76	16.099	0.978	6.08	12.100	20.100
2022525y	1	6 PAR REG	5	BASOPHIL	31	SYSMEX XN	38	4.783	1.232	25.75	2.800	6.800
2022525y	1	6 PAR REG	5	BASOPHIL	35	SYS XNL SR	76	9.774	1.064	10.89	7.300	12.200
2022525y	1	6 PAR REG	6	IMMATURE G	31	SYSMEX XN	38	16.300	1.162	7.13	12.200	20.400
2022525y	1	6 PAR REG	6	IMMATURE G	35	SYS XNL SR	76	17.738	1.062	5.99	13.300	22.200
2022525y	1	6 PAR REG	7	NRBC	31	SYSMEX XN	21	0.000	0.000	0.00	0	2.000

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022521z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	30	61.373	0.974	1.59	46.000	76.700
2022521z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	36	60.686	1.693	2.79	45.500	75.900
2022521z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	30	13.327	0.906	6.80	10.000	16.700
2022521z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	36	10.221	0.503	4.92	7.700	12.800
2022521z	8	3ST	3	Neutrophil	1	KX 21 - Sy	30	25.300	0.984	3.89	19.000	31.600
2022521z	8	3ST	3	Neutrophil	3	ABBOTT C-D	35	28.994	1.217	4.20	21.700	36.200
2022521z	9	3D	1	Lymphocyte	2	AcT Diff 2	19	13.700	0.756	5.52	10.300	17.100
2022521z	9	3D	1	Lymphocyte	4	JT - Coult	11	14.164	0.792	5.59	10.600	17.700
2022521z	9	3D	1	Lymphocyte	6	Emerald Gr	13	14.362	1.332	9.28	10.800	18.000
2022521z	9	3D	2	Mix M/E/Ba	2	AcT Diff 2	19	4.405	0.419	9.50	2.400	6.400
2022521z	9	3D	2	Mix M/E/Ba	4	JT - Coult	11	3.527	0.566	16.04	1.500	5.500
2022521z	9	3D	2	Mix M/E/Ba	6	Emerald Gr	13	2.531	0.223	8.82	0.500	4.500
2022521z	9	3D	3	Neutrophil	2	AcT Diff 2	19	81.879	0.919	1.12	61.400	102.300
2022521z	9	3D	3	Neutrophil	4	JT - Coult	11	82.309	0.935	1.14	61.700	102.900
2022521z	9	3D	3	Neutrophil	6	Emerald Gr	13	83.315	1.079	1.30	62.500	104.100

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
186	DIFF 3 PARAMETER INS	CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE	25	%	OR 2.00	{GREATER}						
2022522z	8 3ST	1 Lymphocyte	1 KX 21 - Sy	30	11.590	0.991	8.55	8.700	14.500				
2022522z	8 3ST	1 Lymphocyte	3 ABBOTT C-D	36	15.439	1.554	10.06	11.600	19.300				
2022522z	8 3ST	2 Mix M/E/Ba	1 KX 21 - Sy	30	18.663	1.344	7.20	14.000	23.300				
2022522z	8 3ST	2 Mix M/E/Ba	3 ABBOTT C-D	36	11.957	1.200	10.03	9.000	14.900				
2022522z	8 3ST	3 Neutrophil	1 KX 21 - Sy	30	69.747	1.487	2.13	52.300	87.200				
2022522z	8 3ST	3 Neutrophil	3 ABBOTT C-D	36	72.589	1.975	2.72	54.400	90.700				
2022522z	9 3D	1 Lymphocyte	2 AcT Diff 2	19	60.411	1.446	2.39	45.300	75.500				
2022522z	9 3D	1 Lymphocyte	4 JT - Coult	11	61.609	2.012	3.27	46.200	77.000				
2022522z	9 3D	1 Lymphocyte	6 Emerald Gr	13	54.362	1.896	3.49	40.800	68.000				
2022522z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	19	8.695	1.268	14.58	6.500	10.900				
2022522z	9 3D	2 Mix M/E/Ba	4 JT - Coult	11	6.527	1.312	20.10	4.500	8.500				
2022522z	9 3D	2 Mix M/E/Ba	6 Emerald Gr	13	10.162	0.869	8.55	7.600	12.700				
2022522z	9 3D	3 Neutrophil	2 AcT Diff 2	18	30.889	1.795	5.81	23.200	38.600				
2022522z	9 3D	3 Neutrophil	4 JT - Coult	12	31.750	2.360	7.43	23.800	39.700				
2022522z	9 3D	3 Neutrophil	6 Emerald Gr	13	35.477	1.754	4.94	26.600	44.300				
2022523z	8 3ST	1 Lymphocyte	1 KX 21 - Sy	30	30.557	1.048	3.43	22.900	38.200				
2022523z	8 3ST	1 Lymphocyte	3 ABBOTT C-D	36	31.377	1.053	3.36	23.500	39.200				
2022523z	8 3ST	2 Mix M/E/Ba	1 KX 21 - Sy	30	16.438	0.698	4.25	12.300	20.500				
2022523z	8 3ST	2 Mix M/E/Ba	3 ABBOTT C-D	36	11.492	0.768	6.69	8.600	14.400				
2022523z	8 3ST	3 Neutrophil	1 KX 21 - Sy	30	52.850	1.110	2.10	39.600	66.100				
2022523z	8 3ST	3 Neutrophil	3 ABBOTT C-D	36	57.124	1.442	2.52	42.800	71.400				
2022523z	9 3D	1 Lymphocyte	2 AcT Diff 2	19	32.384	1.187	3.67	24.300	40.500				
2022523z	9 3D	1 Lymphocyte	4 JT - Coult	11	32.420	1.695	5.23	24.300	40.500				
2022523z	9 3D	1 Lymphocyte	6 Emerald Gr	13	29.446	1.085	3.69	22.100	36.800				
2022523z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	19	6.632	0.691	10.41	4.600	8.600				
2022523z	9 3D	2 Mix M/E/Ba	4 JT - Coult	11	5.745	0.754	13.12	3.700	7.700				
2022523z	9 3D	2 Mix M/E/Ba	6 Emerald Gr	13	5.746	0.332	5.78	3.700	7.700				
2022523z	9 3D	3 Neutrophil	2 AcT Diff 2	19	60.963	1.732	2.84	45.700	76.200				

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY			SUB: 70 GENERAL			GRP: 128 DIFF 3 PARAMETER INS						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022523z	9	3D	3	Neutrophil	4	JT - Coult	11	61.760	1.167	1.89	46.300	77.200
2022523z	9	3D	3	Neutrophil	6	Emerald Gr	13	64.808	1.030	1.59	48.600	81.000
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022524z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	30	30.647	1.179	3.85	23.000	38.300
2022524z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	36	31.446	1.274	4.05	23.600	39.300
2022524z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	30	16.317	0.920	5.64	12.200	20.400
2022524z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	36	11.463	0.738	6.44	8.600	14.300
2022524z	8	3ST	3	Neutrophil	1	KX 21 - Sy	30	53.037	1.157	2.18	39.800	66.300
2022524z	8	3ST	3	Neutrophil	3	ABBOTT C-D	36	57.044	1.878	3.29	42.800	71.300
2022524z	9	3D	1	Lymphocyte	2	AcT Diff 2	19	32.428	1.035	3.19	24.300	40.500
2022524z	9	3D	1	Lymphocyte	4	JT - Coult	11	32.082	1.250	3.90	24.100	40.100
2022524z	9	3D	1	Lymphocyte	6	Emerald Gr	13	29.531	1.304	4.42	22.100	36.900
2022524z	9	3D	2	Mix M/E/Ba	2	AcT Diff 2	19	6.600	0.814	12.34	4.600	8.600
2022524z	9	3D	2	Mix M/E/Ba	4	JT - Coult	11	5.764	0.778	13.51	3.800	7.800
2022524z	9	3D	2	Mix M/E/Ba	6	Emerald Gr	13	5.769	0.365	6.32	3.800	7.800
2022524z	9	3D	3	Neutrophil	2	AcT Diff 2	19	60.684	2.006	3.31	45.500	75.900
2022524z	9	3D	3	Neutrophil	4	JT - Coult	11	62.155	1.220	1.96	46.600	77.700
2022524z	9	3D	3	Neutrophil	6	Emerald Gr	13	64.700	1.129	1.74	48.500	80.900
2022525z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	30	11.372	0.944	8.30	8.500	14.200
2022525z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	37	13.542	1.345	9.93	10.200	16.900
2022525z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	30	18.580	0.921	4.96	13.900	23.200
2022525z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	35	12.000	1.319	10.99	9.000	15.000
2022525z	8	3ST	3	Neutrophil	1	KX 21 - Sy	30	69.897	1.238	1.77	52.400	87.400
2022525z	8	3ST	3	Neutrophil	3	ABBOTT C-D	36	74.383	2.153	2.89	55.800	93.000
2022525z	9	3D	1	Lymphocyte	2	AcT Diff 2	19	60.950	1.208	1.98	45.700	76.200
2022525z	9	3D	1	Lymphocyte	4	JT - Coult	11	61.790	1.462	2.37	46.300	77.200
2022525z	9	3D	1	Lymphocyte	6	Emerald Gr	13	54.438	1.515	2.78	40.800	68.000
2022525z	9	3D	2	Mix M/E/Ba	2	AcT Diff 2	19	8.747	1.220	13.94	6.600	10.900
2022525z	9	3D	2	Mix M/E/Ba	4	JT - Coult	11	6.745	0.819	12.15	4.700	8.700

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 128 DIFF 3 PARAMETER INS

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022525z	9	3D	2	Mix M/E/Ba	6	Emerald Gr	13	10.515	0.762	7.25	7.900	13.100
2022525z	9	3D	3	Neutrophil	2	AcT Diff 2	19	30.505	1.288	4.22	22.900	38.100
2022525z	9	3D	3	Neutrophil	4	JT - Coult	11	31.390	1.926	6.14	23.500	39.200
2022525z	9	3D	3	Neutrophil	6	Emerald Gr	13	35.046	1.136	3.24	26.300	43.800

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 132 COMP BLOOD COUNT NEW

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
549	RED CELL COUNT (RBC)		CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 6 %							
2022-521	1	Sysmex CBC	132	SYSMEX XS			145	2.305	0.028	1.21	2.170	2.440
2022-521	1	Sysmex CBC	141	SYSMEX XN			44	2.282	0.028	1.22	2.150	2.420
2022-521	1	Sysmex CBC	152	Sysmex XN			76	2.270	0.028	1.24	2.130	2.410
2022-521	2	ACT PENTRA	125	COULTER AC			133	5.191	0.077	1.47	4.880	5.500
2022-521	2	ACT PENTRA	130	ABX PENTRA			28	5.189	0.055	1.05	4.880	5.500
2022-521	3	ADVIA 120	116	ADVIA-120			17	5.314	0.076	1.42	5.000	5.630
2022-521	4	AB-CELL DY	115	ABBOTT C-D			121	2.125	0.071	3.32	2.000	2.250
2022-521	5	BECTON D	137	B.C DXH			57	2.535	0.039	1.54	2.380	2.690
2022-521	6	MR Mindray	145	BC-5390			48	2.105	0.030	1.42	1.980	2.230
2022-521	7	DXH500 Ser	149	BC DXH 500			38	5.250	0.077	1.46	4.930	5.560
2022-521	8	3 ST	84	ABBOTT C-D			36	5.740	0.116	2.02	5.400	6.080
2022-521	8	3 ST	98	SYSMEX K-			11	5.687	0.087	1.53	5.350	6.030
2022-521	8	3 ST	138	SY KX-21N			19	5.713	0.039	0.68	5.370	6.060
2022-521	9	3 D	33	COULTER JT			12	5.778	0.122	2.11	5.430	6.130
2022-521	9	3 D	120	COULTER			19	5.749	0.154	2.68	5.400	6.090
2022-522	1	Sysmex CBC	132	SYSMEX XS			145	4.634	0.049	1.06	4.360	4.910
2022-522	1	Sysmex CBC	141	SYSMEX XN			44	4.652	0.055	1.17	4.370	4.930
2022-522	1	Sysmex CBC	152	Sysmex XN			76	4.636	0.058	1.25	4.360	4.910

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-522	2	ACT PENTRA	125 COULTER AC	133	2.361	0.043	1.82	2.220	2.500	
2022-522	2	ACT PENTRA	130 ABX PENTRA	28	2.381	0.053	2.25	2.240	2.520	
2022-522	3	ADVIA 120	116 ADVIA-120	17	2.299	0.021	0.91	2.160	2.440	
2022-522	4	AB-CELL DY	115 ABBOTT C-D	121	4.543	0.166	3.66	4.270	4.820	
2022-522	5	BECTON D	137 B.C DXH	57	4.065	0.050	1.23	3.820	4.310	
2022-522	6	MR Mindray	145 BC-5390	48	4.387	0.069	1.58	4.120	4.650	
2022-522	7	DXH500 Ser	149 BC DXH 500	38	2.450	0.042	1.70	2.300	2.600	
2022-522	8	3 ST	84 ABBOTT C-D	36	2.442	0.069	2.83	2.300	2.590	
2022-522	8	3 ST	98 SYSMEX K-	11	2.415	0.028	1.15	2.270	2.560	
2022-522	8	3 ST	138 SY KX-21N	19	2.394	0.025	1.04	2.250	2.540	
2022-522	9	3 D	33 COULTER JT	12	2.254	0.062	2.73	2.120	2.390	
2022-522	9	3 D	120 COULTER	19	2.292	0.055	2.40	2.150	2.430	
549 RED CELL COUNT (RBC)		CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 6 %						
2022-523	1	Sysmex CBC	132 SYSMEX XS	145	6.128	0.067	1.09	5.760	6.500	
2022-523	1	Sysmex CBC	141 SYSMEX XN	44	6.160	0.067	1.09	5.790	6.530	
2022-523	1	Sysmex CBC	152 Sysmex XN	76	6.170	0.070	1.14	5.800	6.540	
2022-523	2	ACT PENTRA	125 COULTER AC	133	4.489	0.067	1.50	4.220	4.760	
2022-523	2	ACT PENTRA	130 ABX PENTRA	28	4.500	0.052	1.16	4.230	4.770	
2022-523	3	ADVIA 120	116 ADVIA-120	17	4.340	0.074	1.70	4.080	4.600	
2022-523	4	AB-CELL DY	115 ABBOTT C-D	121	6.261	0.226	3.62	5.890	6.640	
2022-523	5	BECTON D	137 B.C DXH	57	6.135	0.081	1.32	5.770	6.500	
2022-523	6	MR Mindray	145 BC-5390	48	4.403	0.067	1.52	4.140	4.670	
2022-523	7	DXH500 Ser	149 BC DXH 500	38	4.713	0.062	1.32	4.430	5.000	
2022-523	8	3 ST	84 ABBOTT C-D	36	4.143	0.086	2.07	3.890	4.390	
2022-523	8	3 ST	98 SYSMEX K-	11	4.055	0.049	1.21	3.810	4.300	
2022-523	8	3 ST	138 SY KX-21N	19	4.054	0.051	1.26	3.810	4.300	
2022-523	9	3 D	33 COULTER JT	12	4.753	0.115	2.41	4.470	5.040	
2022-523	9	3 D	120 COULTER	19	4.697	0.098	2.09	4.420	4.980	
2022-524	1	Sysmex CBC	132 SYSMEX XS	145	5.620	0.062	1.11	5.280	5.960	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-524	1	Sysmex CBC	141	SYSMEX XN	44	5.650	0.064	1.14	5.310	5.990	
2022-524	1	Sysmex CBC	152	Sysmex XN	76	5.655	0.061	1.08	5.320	5.990	
2022-524	2	ACT PENTRA	125	COULTER AC	133	4.481	0.063	1.41	4.210	4.750	
2022-524	2	ACT PENTRA	130	ABX PENTRA	28	4.474	0.069	1.54	4.210	4.740	
2022-524	3	ADVIA 120	116	ADVIA-120	17	4.334	0.064	1.47	4.070	4.590	
2022-524	4	AB-CELL DY	115	ABBOTT C-D	121	5.029	0.162	3.22	4.730	5.330	
2022-524	5	BECTON D	137	B.C DXH	57	5.548	0.067	1.20	5.220	5.880	
2022-524	6	MR Mindray	145	BC-5390	48	5.306	0.090	1.70	4.990	5.620	
2022-524	7	DXH500 Ser	149	BC DXH 500	38	4.728	0.062	1.32	4.440	5.010	
2022-524	8	3 ST	84	ABBOTT C-D	36	4.119	0.104	2.51	3.870	4.370	
2022-524	8	3 ST	98	SYSMEX K-	11	4.055	0.044	1.07	3.810	4.300	
2022-524	8	3 ST	138	SY KX-21N	19	4.062	0.049	1.21	3.820	4.310	
2022-524	9	3 D	33	COULTER JT	12	4.759	0.089	1.86	4.470	5.040	
2022-524	9	3 D	120	COULTER	19	4.721	0.115	2.43	4.440	5.000	
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 6 %								
2022-525	1	Sysmex CBC	132	SYSMEX XS	145	2.304	0.028	1.23	2.170	2.440	
2022-525	1	Sysmex CBC	141	SYSMEX XN	44	2.279	0.031	1.37	2.140	2.420	
2022-525	1	Sysmex CBC	152	Sysmex XN	76	2.269	0.029	1.28	2.130	2.410	
2022-525	2	ACT PENTRA	125	COULTER AC	133	2.361	0.047	1.98	2.220	2.500	
2022-525	2	ACT PENTRA	130	ABX PENTRA	28	2.378	0.044	1.85	2.240	2.520	
2022-525	3	ADVIA 120	116	ADVIA-120	17	2.300	0.029	1.26	2.160	2.440	
2022-525	4	AB-CELL DY	115	ABBOTT C-D	121	2.129	0.055	2.60	2.000	2.260	
2022-525	5	BECTON D	137	B.C DXH	57	2.531	0.032	1.27	2.380	2.680	
2022-525	6	MR Mindray	145	BC-5390	48	2.105	0.040	1.88	1.980	2.230	
2022-525	7	DXH500 Ser	149	BC DXH 500	38	2.447	0.042	1.73	2.300	2.590	
2022-525	8	3 ST	84	ABBOTT C-D	36	2.440	0.067	2.73	2.290	2.590	
2022-525	8	3 ST	98	SYSMEX K-	11	2.408	0.023	0.95	2.260	2.550	
2022-525	8	3 ST	138	SY KX-21N	19	2.406	0.025	1.05	2.260	2.550	
2022-525	9	3 D	33	COULTER JT	12	2.262	0.061	2.71	2.130	2.400	
2022-525	9	3 D	120	COULTER	19	2.279	0.073	3.18	2.140	2.420	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
550	HEMATOCRIT (HCT)	CLIA TEST ID #: 785	EVALUATION CRITERIA: TARGET VALUE 6 %								
2022-521	1	132	145	18.092	0.309	1.71	17.000	19.200			
2022-521	1	141	44	17.575	0.319	1.82	16.500	18.600			
2022-521	1	152	76	17.326	2.032	11.73	16.300	18.400			
2022-521	2	125	132	45.937	0.786	1.71	43.200	48.700			
2022-521	2	130	28	46.556	0.789	1.69	43.800	49.300			
2022-521	3	116	17	47.471	1.071	2.26	44.600	50.300			
2022-521	4	115	121	15.310	0.532	3.47	14.400	16.200			
2022-521	5	137	57	20.888	0.362	1.73	19.600	22.100			
2022-521	6	145	48	17.019	0.399	2.35	16.000	18.000			
2022-521	7	149	38	49.076	1.000	2.04	46.100	52.000			
2022-521	8	84	36	52.963	1.150	2.17	49.800	56.100			
2022-521	8	98	12	49.217	1.007	2.05	46.300	52.200			
2022-521	8	138	19	49.563	0.895	1.81	46.600	52.500			
2022-521	9	33	12	52.400	1.634	3.12	49.300	55.500			
2022-521	9	120	19	52.468	1.611	3.07	49.300	55.600			
2022-522	1	132	145	39.745	0.753	1.89	37.400	42.100			
2022-522	1	141	44	39.434	0.752	1.91	37.100	41.800			
2022-522	1	152	76	39.280	0.809	2.06	36.900	41.600			
2022-522	2	125	132	17.892	0.394	2.20	16.800	19.000			
2022-522	2	130	28	18.211	0.499	2.74	17.100	19.300			
2022-522	3	116	17	15.847	0.394	2.49	14.900	16.800			
2022-522	4	115	121	37.643	1.392	3.70	35.400	39.900			
2022-522	5	137	57	37.367	0.588	1.57	35.100	39.600			
2022-522	6	145	48	37.481	0.927	2.47	35.200	39.700			
2022-522	7	149	38	19.482	0.425	2.18	18.300	20.700			
2022-522	8	84	36	18.339	0.693	3.78	17.200	19.400			
2022-522	8	98	12	17.192	0.382	2.22	16.200	18.200			
2022-522	8	138	19	17.063	0.301	1.77	16.000	18.100			

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-522	9 3 D	33 COULTER JT			12	16.808	0.527	3.13	15.800	17.800	
2022-522	9 3 D	120 COULTER			19	17.158	0.606	3.53	16.100	18.200	
550 HEMATOCRIT (HCT)		CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 6 %							
2022-523	1 Sysmex CBC	132 SYSMEX XS			145	57.237	1.120	1.96	53.800	60.700	
2022-523	1 Sysmex CBC	141 SYSMEX XN			44	56.786	0.977	1.72	53.400	60.200	
2022-523	1 Sysmex CBC	152 Sysmex XN			76	56.637	1.088	1.92	53.200	60.000	
2022-523	2 ACT PENTRA	125 COULTER AC			132	37.405	0.659	1.76	35.200	39.600	
2022-523	2 ACT PENTRA	130 ABX PENTRA			28	38.186	0.724	1.90	35.900	40.500	
2022-523	3 ADVIA 120	116 ADVIA-120			17	36.435	1.081	2.97	34.200	38.600	
2022-523	4 AB-CELL DY	115 ABBOTT C-D			121	53.141	2.045	3.85	50.000	56.300	
2022-523	5 BECTON D	137 B.C DXH			57	60.677	0.950	1.57	57.000	64.300	
2022-523	6 MR Mindray	145 BC-5390			48	37.519	0.922	2.46	35.300	39.800	
2022-523	7 DXH500 Ser	149 BC DXH 500			38	41.826	0.755	1.81	39.300	44.300	
2022-523	8 3 ST	84 ABBOTT C-D			36	34.891	0.893	2.56	32.800	37.000	
2022-523	8 3 ST	98 SYSMEX K-			12	31.808	0.565	1.78	29.900	33.700	
2022-523	8 3 ST	138 SY KX-21N			19	31.789	0.483	1.52	29.900	33.700	
2022-523	9 3 D	33 COULTER JT			12	39.300	1.092	2.78	36.900	41.700	
2022-523	9 3 D	120 COULTER			19	39.179	1.075	2.74	36.800	41.500	
2022-524	1 Sysmex CBC	132 SYSMEX XS			145	52.439	0.957	1.83	49.300	55.600	
2022-524	1 Sysmex CBC	141 SYSMEX XN			44	51.741	0.977	1.89	48.600	54.800	
2022-524	1 Sysmex CBC	152 Sysmex XN			76	51.672	1.004	1.94	48.600	54.800	
2022-524	2 ACT PENTRA	125 COULTER AC			132	37.381	0.697	1.87	35.100	39.600	
2022-524	2 ACT PENTRA	130 ABX PENTRA			28	37.821	0.720	1.90	35.600	40.100	
2022-524	3 ADVIA 120	116 ADVIA-120			17	36.335	1.047	2.88	34.200	38.500	
2022-524	4 AB-CELL DY	115 ABBOTT C-D			121	44.021	1.597	3.63	41.400	46.700	
2022-524	5 BECTON D	137 B.C DXH			57	55.095	0.790	1.43	51.800	58.400	
2022-524	6 MR Mindray	145 BC-5390			48	48.031	1.191	2.48	45.100	50.900	
2022-524	7 DXH500 Ser	149 BC DXH 500			38	41.995	0.738	1.76	39.500	44.500	
2022-524	8 3 ST	84 ABBOTT C-D			36	34.739	1.250	3.60	32.700	36.800	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-524	8 3 ST	98 SYSMEX K-			12	31.875	0.582	1.83	30.000	33.800	
2022-524	8 3 ST	138 SY KX-21N			19	31.979	0.693	2.17	30.100	33.900	
2022-524	9 3 D	33 COULTER JT			12	39.308	0.798	2.03	36.900	41.700	
2022-524	9 3 D	120 COULTER			19	39.342	1.202	3.06	37.000	41.700	
550 HEMATOCRIT (HCT)		CLIA TEST ID #: 785							EVALUATION CRITERIA: TARGET VALUE 6 %		
2022-525	1 Sysmex CBC	132 SYSMEX XS			145	18.063	0.326	1.80	17.000	19.100	
2022-525	1 Sysmex CBC	141 SYSMEX XN			44	17.598	0.322	1.83	16.500	18.700	
2022-525	1 Sysmex CBC	152 Sysmex XN			76	17.589	0.383	2.18	16.500	18.600	
2022-525	2 ACT PENTRA	125 COULTER AC			132	17.908	0.377	2.11	16.800	19.000	
2022-525	2 ACT PENTRA	130 ABX PENTRA			28	18.207	0.418	2.30	17.100	19.300	
2022-525	3 ADVIA 120	116 ADVIA-120			17	15.847	0.413	2.61	14.900	16.800	
2022-525	4 AB-CELL DY	115 ABBOTT C-D			121	15.352	0.423	2.76	14.400	16.300	
2022-525	5 BECTON D	137 B.C DXH			57	20.909	0.315	1.51	19.700	22.200	
2022-525	6 MR Mindray	145 BC-5390			48	16.977	0.394	2.32	16.000	18.000	
2022-525	7 DXH500 Ser	149 BC DXH 500			38	19.489	0.470	2.41	18.300	20.700	
2022-525	8 3 ST	84 ABBOTT C-D			36	18.342	0.621	3.38	17.200	19.400	
2022-525	8 3 ST	98 SYSMEX K-			12	17.150	0.307	1.79	16.100	18.200	
2022-525	8 3 ST	138 SY KX-21N			19	17.121	0.226	1.32	16.100	18.100	
2022-525	9 3 D	33 COULTER JT			12	16.817	0.513	3.05	15.800	17.800	
2022-525	9 3 D	120 COULTER			19	17.005	0.621	3.65	16.000	18.000	
551 HEMOGLOBIN (HGB)		CLIA TEST ID #: 795							EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}		
2022-521	1 Sysmex CBC	132 SYSMEX XS			146	5.888	0.075	1.28	5.500	6.300	
2022-521	1 Sysmex CBC	141 SYSMEX XN			43	5.967	0.077	1.29	5.500	6.400	
2022-521	1 Sysmex CBC	152 Sysmex XN			76	5.964	0.068	1.14	5.500	6.400	
2022-521	2 ACT PENTRA	125 COULTER AC			133	16.700	0.226	1.36	15.500	17.900	
2022-521	2 ACT PENTRA	130 ABX PENTRA			28	16.948	0.220	1.30	15.800	18.100	
2022-521	3 ADVIA 120	116 ADVIA-120			17	17.619	0.298	1.69	16.400	18.900	
2022-521	4 AB-CELL DY	115 ABBOTT C-D			121	5.845	0.161	2.75	5.400	6.300	
2022-521	5 BECTON D	137 B.C DXH			57	6.582	0.073	1.12	6.100	7.000	
2022-521	6 MR Mindray	145 BC-5390			48	5.702	0.097	1.70	5.300	6.100	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-521	7 DXH500 Ser	149 BC DXH 500			38	17.484	0.252	1.44	16.300	18.700	
2022-521	8 3 ST	84 ABBOTT C-D			36	18.175	0.354	1.95	16.900	19.400	
2022-521	8 3 ST	98 SYSMEX K-			12	18.342	0.317	1.73	17.100	19.600	
2022-521	8 3 ST	138 SY KX-21N			19	18.258	0.196	1.07	17.000	19.500	
2022-521	9 3 D	33 COULTER JT			12	18.833	0.566	3.01	17.500	20.200	
2022-521	9 3 D	120 COULTER			19	18.295	0.450	2.46	17.000	19.600	
551 HEMOGLOBIN (HGB)		CLIA TEST ID #: 795		EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}							
2022-522	1 Sysmex CBC	132 SYSMEX XS			146	13.255	0.136	1.03	12.300	14.200	
2022-522	1 Sysmex CBC	141 SYSMEX XN			43	13.330	0.136	1.02	12.400	14.300	
2022-522	1 Sysmex CBC	152 Sysmex XN			76	13.282	0.102	0.77	12.400	14.200	
2022-522	2 ACT PENTRA	125 COULTER AC			133	6.279	0.097	1.55	5.800	6.700	
2022-522	2 ACT PENTRA	130 ABX PENTRA			28	6.196	0.105	1.70	5.800	6.600	
2022-522	3 ADVIA 120	116 ADVIA-120			17	5.882	0.098	1.67	5.500	6.300	
2022-522	4 AB-CELL DY	115 ABBOTT C-D			121	13.880	0.255	1.84	12.900	14.900	
2022-522	5 BECTON D	137 B.C DXH			57	11.967	0.150	1.26	11.100	12.800	
2022-522	6 MR Mindray	145 BC-5390			48	12.857	0.165	1.28	12.000	13.800	
2022-522	7 DXH500 Ser	149 BC DXH 500			38	6.805	0.126	1.84	6.300	7.300	
2022-522	8 3 ST	84 ABBOTT C-D			36	6.540	0.120	1.83	6.100	7.000	
2022-522	8 3 ST	98 SYSMEX K-			12	6.267	0.085	1.36	5.800	6.700	
2022-522	8 3 ST	138 SY KX-21N			19	6.321	0.095	1.50	5.900	6.800	
2022-522	9 3 D	33 COULTER JT			12	5.775	0.130	2.25	5.400	6.200	
2022-522	9 3 D	120 COULTER			19	5.837	0.187	3.20	5.400	6.200	
2022-523	1 Sysmex CBC	132 SYSMEX XS			146	19.261	0.193	1.00	17.900	20.600	
2022-523	1 Sysmex CBC	141 SYSMEX XN			43	19.269	0.195	1.01	17.900	20.600	
2022-523	1 Sysmex CBC	152 Sysmex XN			76	19.193	0.152	0.79	17.800	20.500	
2022-523	2 ACT PENTRA	125 COULTER AC			133	13.855	0.177	1.28	12.900	14.800	
2022-523	2 ACT PENTRA	130 ABX PENTRA			28	14.039	0.182	1.30	13.100	15.000	
2022-523	3 ADVIA 120	116 ADVIA-120			17	13.371	0.181	1.35	12.400	14.300	
2022-523	4 AB-CELL DY	115 ABBOTT C-D			121	19.136	0.349	1.83	17.800	20.500	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-523	5	BECTON D	137	B.C DXH	57	18.965	0.197	1.04	17.600	20.300	
2022-523	6	MR Mindray	145	BC-5390	48	12.870	0.176	1.37	12.000	13.800	
2022-523	7	DXH500 Ser	149	BC DXH 500	38	14.761	0.153	1.04	13.700	15.800	
2022-523	8	3 ST	84	ABBOTT C-D	36	12.111	0.208	1.72	11.300	13.000	
2022-523	8	3 ST	98	SYSMEX K-	12	12.042	0.202	1.68	11.200	12.900	
2022-523	8	3 ST	138	SY KX-21N	19	12.005	0.143	1.19	11.200	12.800	
2022-523	9	3 D	33	COULTER JT	12	13.875	0.235	1.69	12.900	14.800	
2022-523	9	3 D	120	COULTER	19	13.679	0.317	2.32	12.700	14.600	
551	HEMOGLOBIN (HGB)		CLIA	TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}						
2022-524	1	Sysmex CBC	132	SYSMEX XS	146	17.666	0.159	0.90	16.400	18.900	
2022-524	1	Sysmex CBC	141	SYSMEX XN	43	17.651	0.174	0.99	16.400	18.900	
2022-524	1	Sysmex CBC	152	Sysmex XN	76	17.611	0.118	0.67	16.400	18.800	
2022-524	2	ACT PENTRA	125	COULTER AC	133	13.873	0.213	1.53	12.900	14.800	
2022-524	2	ACT PENTRA	130	ABX PENTRA	28	13.993	0.173	1.24	13.000	15.000	
2022-524	3	ADVIA 120	116	ADVIA-120	17	13.318	0.162	1.21	12.400	14.200	
2022-524	4	AB-CELL DY	115	ABBOTT C-D	121	16.762	0.263	1.57	15.600	17.900	
2022-524	5	BECTON D	137	B.C DXH	57	17.147	0.172	1.00	15.900	18.300	
2022-524	6	MR Mindray	145	BC-5390	48	16.646	0.236	1.42	15.500	17.800	
2022-524	7	DXH500 Ser	149	BC DXH 500	38	14.747	0.160	1.09	13.700	15.800	
2022-524	8	3 ST	84	ABBOTT C-D	36	12.056	0.229	1.90	11.200	12.900	
2022-524	8	3 ST	98	SYSMEX K-	12	12.008	0.225	1.88	11.200	12.800	
2022-524	8	3 ST	138	SY KX-21N	19	12.026	0.165	1.37	11.200	12.900	
2022-524	9	3 D	33	COULTER JT	12	13.958	0.340	2.44	13.000	14.900	
2022-524	9	3 D	120	COULTER	19	13.737	0.291	2.12	12.800	14.700	
2022-525	1	Sysmex CBC	132	SYSMEX XS	146	5.910	0.084	1.42	5.500	6.300	
2022-525	1	Sysmex CBC	141	SYSMEX XN	43	6.021	0.085	1.41	5.600	6.400	
2022-525	1	Sysmex CBC	152	Sysmex XN	76	5.978	0.062	1.04	5.600	6.400	
2022-525	2	ACT PENTRA	125	COULTER AC	133	6.267	0.098	1.56	5.800	6.700	
2022-525	2	ACT PENTRA	130	ABX PENTRA	28	6.221	0.101	1.63	5.800	6.700	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-525	3	ADVIA 120	116 ADVIA-120	17	5.853	0.085	1.45	5.400	6.300
2022-525	4	AB-CELL DY	115 ABBOTT C-D	121	5.836	0.159	2.73	5.400	6.200
2022-525	5	BECTON D	137 B.C DXH	57	6.595	0.083	1.26	6.100	7.100
2022-525	6	MR Mindray	145 BC-5390	48	5.702	0.086	1.51	5.300	6.100
2022-525	7	DXH500 Ser	149 BC DXH 500	38	6.806	0.088	1.29	6.300	7.300
2022-525	8	3 ST	84 ABBOTT C-D	36	6.514	0.133	2.05	6.100	7.000
2022-525	8	3 ST	98 SYSMEX K-	12	6.292	0.076	1.21	5.900	6.700
2022-525	8	3 ST	138 SY KX-21N	19	6.337	0.122	1.93	5.900	6.800
2022-525	9	3 D	33 COULTER JT	12	5.825	0.130	2.23	5.400	6.200
2022-525	9	3 D	120 COULTER	19	5.874	0.240	4.09	5.500	6.300
552 WHITE CELL COUNT(WBC		CLIA TEST ID #: 805		EVALUATION CRITERIA: TARGET VALUE 15 %					
2022-521	1	Sysmex CBC	132 SYSMEX XS	145	4.166	0.245	5.89	3.500	4.800
2022-521	1	Sysmex CBC	141 SYSMEX XN	45	4.120	0.189	4.59	3.500	4.700
2022-521	1	Sysmex CBC	152 Sysmex XN	75	3.741	0.137	3.65	3.200	4.300
2022-521	2	ACT PENTRA	125 COULTER AC	133	18.089	0.821	4.54	15.400	20.800
2022-521	2	ACT PENTRA	130 ABX PENTRA	28	17.682	0.416	2.35	15.000	20.300
2022-521	3	ADVIA 120	116 ADVIA-120	17	17.294	0.711	4.11	14.700	19.900
2022-521	4	AB-CELL DY	115 ABBOTT C-D	121	3.010	0.112	3.72	2.600	3.500
2022-521	5	BECTON D	137 B.C DXH	57	4.080	0.199	4.87	3.500	4.700
2022-521	6	MR Mindray	145 BC-5390	48	3.375	0.118	3.50	2.900	3.900
2022-521	7	DXH500 Ser	149 BC DXH 500	38	18.908	0.485	2.57	16.100	21.700
2022-521	8	3 ST	84 ABBOTT C-D	36	19.464	1.257	6.46	16.500	22.400
2022-521	8	3 ST	98 SYSMEX K-	12	19.850	0.355	1.79	16.900	22.800
2022-521	8	3 ST	138 SY KX-21N	19	19.974	0.584	2.92	17.000	23.000
2022-521	9	3 D	33 COULTER JT	12	21.725	0.962	4.43	18.500	25.000
2022-521	9	3 D	120 COULTER	19	20.795	0.672	3.23	17.700	23.900
2022-522	1	Sysmex CBC	132 SYSMEX XS	145	7.194	0.383	5.33	6.100	8.300
2022-522	1	Sysmex CBC	141 SYSMEX XN	45	7.522	0.287	3.82	6.400	8.700
2022-522	1	Sysmex CBC	152 Sysmex XN	75	7.049	0.233	3.30	6.000	8.100

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-522	2	ACT PENTRA	125 COULTER AC	133	2.483	0.118	4.77	2.100	2.900
2022-522	2	ACT PENTRA	130 ABX PENTRA	28	2.432	0.071	2.92	2.100	2.800
2022-522	3	ADVIA 120	116 ADVIA-120	17	3.071	0.082	2.68	2.600	3.500
2022-522	4	AB-CELL DY	115 ABBOTT C-D	121	7.566	0.242	3.19	6.400	8.700
2022-522	5	BECTON D	137 B.C DXH	57	10.435	0.216	2.07	8.900	12.000
2022-522	6	MR Mindray	145 BC-5390	48	8.313	0.202	2.43	7.100	9.600
2022-522	7	DXH500 Ser	149 BC DXH 500	38	2.347	0.109	4.66	2.000	2.700
2022-522	8	3 ST	84 ABBOTT C-D	36	2.974	0.218	7.34	2.500	3.400
2022-522	8	3 ST	98 SYSMEX K-	12	2.775	0.072	2.60	2.400	3.200
2022-522	8	3 ST	138 SY KX-21N	19	2.795	0.076	2.72	2.400	3.200
2022-522	9	3 D	33 COULTER JT	12	2.008	0.076	3.78	1.700	2.300
2022-522	9	3 D	120 COULTER	19	2.158	0.166	7.71	1.800	2.500
552 WHITE CELL COUNT(WBC		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-523	1	Sysmex CBC	132 SYSMEX XS	145	22.608	0.558	2.47	19.200	26.000
2022-523	1	Sysmex CBC	141 SYSMEX XN	45	22.930	0.360	1.57	19.500	26.400
2022-523	1	Sysmex CBC	152 Sysmex XN	75	22.587	0.422	1.87	19.200	26.000
2022-523	2	ACT PENTRA	125 COULTER AC	133	7.440	0.341	4.58	6.300	8.600
2022-523	2	ACT PENTRA	130 ABX PENTRA	28	7.270	0.154	2.11	6.200	8.400
2022-523	3	ADVIA 120	116 ADVIA-120	17	7.412	0.283	3.81	6.300	8.500
2022-523	4	AB-CELL DY	115 ABBOTT C-D	121	9.790	0.286	2.93	8.300	11.300
2022-523	5	BECTON D	137 B.C DXH	57	23.451	0.488	2.08	19.900	27.000
2022-523	6	MR Mindray	145 BC-5390	48	8.317	0.180	2.17	7.100	9.600
2022-523	7	DXH500 Ser	149 BC DXH 500	38	7.274	0.227	3.12	6.200	8.400
2022-523	8	3 ST	84 ABBOTT C-D	36	7.869	0.575	7.31	6.700	9.000
2022-523	8	3 ST	98 SYSMEX K-	12	7.983	0.211	2.65	6.800	9.200
2022-523	8	3 ST	138 SY KX-21N	19	7.984	0.250	3.13	6.800	9.200
2022-523	9	3 D	33 COULTER JT	12	8.158	0.429	5.26	6.900	9.400
2022-523	9	3 D	120 COULTER	19	8.100	0.418	5.16	6.900	9.300
2022-524	1	Sysmex CBC	132 SYSMEX XS	145	20.944	0.514	2.45	17.800	24.100

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-524	1	Sysmex CBC	141 SYSMEX XN	45	21.158	0.318	1.50	18.000	24.300
2022-524	1	Sysmex CBC	152 Sysmex XN	75	20.955	0.425	2.03	17.800	24.100
2022-524	2	ACT PENTRA	125 COULTER AC	133	7.428	0.341	4.58	6.300	8.500
2022-524	2	ACT PENTRA	130 ABX PENTRA	28	7.244	0.131	1.81	6.200	8.300
2022-524	3	ADVIA 120	116 ADVIA-120	17	7.424	0.278	3.74	6.300	8.500
2022-524	4	AB-CELL DY	115 ABBOTT C-D	121	20.054	0.512	2.55	17.000	23.100
2022-524	5	BECTON D	137 B.C DXH	57	21.818	0.444	2.04	18.500	25.100
2022-524	6	MR Mindray	145 BC-5390	48	18.483	0.367	1.99	15.700	21.300
2022-524	7	DXH500 Ser	149 BC DXH 500	38	7.305	0.236	3.23	6.200	8.400
2022-524	8	3 ST	84 ABBOTT C-D	36	7.864	0.529	6.72	6.700	9.000
2022-524	8	3 ST	98 SYSMEX K-	12	7.975	0.153	1.92	6.800	9.200
2022-524	8	3 ST	138 SY KX-21N	19	7.989	0.205	2.56	6.800	9.200
2022-524	9	3 D	33 COULTER JT	12	8.225	0.317	3.85	7.000	9.500
2022-524	9	3 D	120 COULTER	19	8.117	0.356	4.39	6.900	9.300
552 WHITE CELL COUNT(WBC		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-525	1	Sysmex CBC	132 SYSMEX XS	145	4.245	0.161	3.80	3.600	4.900
2022-525	1	Sysmex CBC	141 SYSMEX XN	45	4.109	0.198	4.81	3.500	4.700
2022-525	1	Sysmex CBC	152 Sysmex XN	75	3.769	0.151	4.02	3.200	4.300
2022-525	2	ACT PENTRA	125 COULTER AC	133	2.494	0.124	4.98	2.100	2.900
2022-525	2	ACT PENTRA	130 ABX PENTRA	28	2.457	0.090	3.68	2.100	2.800
2022-525	3	ADVIA 120	116 ADVIA-120	17	3.056	0.086	2.83	2.600	3.500
2022-525	4	AB-CELL DY	115 ABBOTT C-D	121	3.055	0.150	4.91	2.600	3.500
2022-525	5	BECTON D	137 B.C DXH	57	4.147	0.186	4.47	3.500	4.800
2022-525	6	MR Mindray	145 BC-5390	48	3.404	0.104	3.06	2.900	3.900
2022-525	7	DXH500 Ser	149 BC DXH 500	38	2.338	0.126	5.39	2.000	2.700
2022-525	8	3 ST	84 ABBOTT C-D	36	2.889	0.215	7.44	2.500	3.300
2022-525	8	3 ST	98 SYSMEX K-	12	2.775	0.060	2.14	2.400	3.200
2022-525	8	3 ST	138 SY KX-21N	19	2.811	0.097	3.44	2.400	3.200
2022-525	9	3 D	33 COULTER JT	12	2.000	0.082	4.08	1.700	2.300
2022-525	9	3 D	120 COULTER	19	2.100	0.145	6.92	1.800	2.400

Participant Summary
MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
553 PLATELET COUNT		CLIA TEST ID #: 815				EVALUATION CRITERIA: TARGET VALUE 25 %					
2022-521	1	SYSMEX CBC	75	SYSMEX XT	10	56.800	5.344	9.41	43.000	71.000	
2022-521	1	SYSMEX CBC	79	SYSMEX XS	145	54.194	3.083	5.69	41.000	68.000	
2022-521	1	SYSMEX CBC	87	SYSMEX XN	45	49.500	2.607	5.27	37.000	62.000	
2022-521	1	SYSMEX CBC	98	SYSMEX 350	74	49.446	2.707	5.47	37.000	62.000	
2022-521	2	ACT5 PENTR	73	COULTER AC	129	480.242	19.734	4.11	360.000	600.000	
2022-521	2	ACT5 PENTR	78	ABX PENTRA	28	476.750	19.143	4.02	358.000	596.000	
2022-521	3	ADVIA 120	64	ADVIA-120	17	476.647	37.801	7.93	357.000	596.000	
2022-521	4	AB- CELL-D	63	ABBOTT C-D	118	85.795	6.769	7.89	64.000	107.000	
2022-521	5	BECTON D	83	B.C600,800	58	85.069	3.145	3.70	64.000	106.000	
2022-521	6	MR Mindray	91	BC-5390	48	51.298	3.107	6.06	38.000	64.000	
2022-521	8	3 ST	31	ABBOTT C-D	37	388.778	37.591	9.67	292.000	486.000	
2022-521	8	3 ST	39	SYSMEX K-	11	391.545	19.672	5.02	294.000	489.000	
2022-521	8	3 ST	84	KX21,300	20	404.474	14.837	3.67	303.000	506.000	
2022-521	9	3 D	50	COULT.JT,M	11	587.273	23.856	4.06	440.000	734.000	
2022-521	9	3 D	68	COULTERAcT	19	577.684	25.039	4.33	433.000	722.000	
2022-521	10	DxH	94	BC DXH 500	38	510.316	32.862	6.44	383.000	638.000	
2022-522	1	SYSMEX CBC	75	SYSMEX XT	10	206.700	14.718	7.12	155.000	258.000	
2022-522	1	SYSMEX CBC	79	SYSMEX XS	145	195.268	9.473	4.85	146.000	244.000	
2022-522	1	SYSMEX CBC	87	SYSMEX XN	45	201.341	7.195	3.57	151.000	252.000	
2022-522	1	SYSMEX CBC	98	SYSMEX 350	74	195.216	12.945	6.63	146.000	244.000	
2022-522	2	ACT5 PENTR	73	COULTER AC	129	70.318	5.247	7.46	53.000	88.000	
2022-522	2	ACT5 PENTR	78	ABX PENTRA	28	70.607	3.783	5.36	53.000	88.000	
2022-522	3	ADVIA 120	64	ADVIA-120	17	60.294	5.096	8.45	45.000	75.000	
2022-522	4	AB- CELL-D	63	ABBOTT C-D	118	285.145	13.983	4.90	214.000	356.000	
2022-522	5	BECTON D	83	B.C600,800	58	270.638	7.723	2.85	203.000	338.000	
2022-522	6	MR Mindray	91	BC-5390	48	255.313	9.285	3.64	191.000	319.000	
2022-522	8	3 ST	31	ABBOTT C-D	37	66.139	7.032	10.63	50.000	83.000	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-522	8 3 ST	39 SYSMEX K-			11	61.727	2.339	3.79	46.000	77.000	
2022-522	8 3 ST	84 KX21,300			20	63.150	4.757	7.53	47.000	79.000	
2022-522	9 3 D	50 COULT.JT,M			11	73.818	2.855	3.87	55.000	92.000	
2022-522	9 3 D	68 COULTERAcT			19	74.368	3.702	4.98	56.000	93.000	
2022-522	10 DxH	94 BC DXH 500			38	85.553	6.664	7.79	64.000	107.000	
553	PLATELET COUNT	CLIA TEST ID #: 815	EVALUATION CRITERIA: TARGET VALUE 25 %								
2022-523	1 SYSMEX CBC	75 SYSMEX XT			10	395.600	35.333	8.93	297.000	495.000	
2022-523	1 SYSMEX CBC	79 SYSMEX XS			145	361.064	20.631	5.71	271.000	451.000	
2022-523	1 SYSMEX CBC	87 SYSMEX XN			45	398.279	14.554	3.65	299.000	498.000	
2022-523	1 SYSMEX CBC	98 SYSMEX 350			74	386.479	30.013	7.77	290.000	483.000	
2022-523	2 ACT5 PENTR	73 COULTER AC			129	254.805	11.212	4.40	191.000	319.000	
2022-523	2 ACT5 PENTR	78 ABX PENTRA			28	258.107	10.824	4.19	194.000	323.000	
2022-523	3 ADVIA 120	64 ADVIA-120			17	236.176	20.563	8.71	177.000	295.000	
2022-523	4 AB- CELL-D	63 ABBOTT C-D			118	151.542	17.166	11.33	114.000	189.000	
2022-523	5 BECTON D	83 B.C600,800			58	480.397	14.433	3.00	360.000	600.000	
2022-523	6 MR Mindray	91 BC-5390			48	255.851	10.281	4.02	192.000	320.000	
2022-523	8 3 ST	31 ABBOTT C-D			37	199.351	18.600	9.33	150.000	249.000	
2022-523	8 3 ST	39 SYSMEX K-			11	198.818	9.023	4.54	149.000	249.000	
2022-523	8 3 ST	84 KX21,300			20	202.900	14.899	7.34	152.000	254.000	
2022-523	9 3 D	50 COULT.JT,M			11	270.455	12.250	4.53	203.000	338.000	
2022-523	9 3 D	68 COULTERAcT			19	265.421	11.357	4.28	199.000	332.000	
2022-523	10 DxH	94 BC DXH 500			38	257.514	13.568	5.27	193.000	322.000	
2022-524	1 SYSMEX CBC	75 SYSMEX XT			10	404.500	42.891	10.60	303.000	506.000	
2022-524	1 SYSMEX CBC	79 SYSMEX XS			145	371.971	27.515	7.40	279.000	465.000	
2022-524	1 SYSMEX CBC	87 SYSMEX XN			45	407.295	13.664	3.35	305.000	509.000	
2022-524	1 SYSMEX CBC	98 SYSMEX 350			74	386.096	39.134	10.14	290.000	483.000	
2022-524	2 ACT5 PENTR	73 COULTER AC			129	254.180	10.834	4.26	191.000	318.000	
2022-524	2 ACT5 PENTR	78 ABX PENTRA			28	257.821	10.830	4.20	193.000	322.000	
2022-524	3 ADVIA 120	64 ADVIA-120			17	238.353	17.882	7.50	179.000	298.000	

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-524	4 AB- CELL-D	63 ABBOTT C-D		118	522.855	25.565	4.89	392.000	654.000		
2022-524	5 BECTON D	83 B.C600,800		58	452.983	10.895	2.41	340.000	566.000		
2022-524	6 MR Mindray	91 BC-5390		48	541.553	14.532	2.68	406.000	677.000		
2022-524	8 3 ST	31 ABBOTT C-D		37	195.861	17.366	8.87	147.000	245.000		
2022-524	8 3 ST	39 SYSMEX K-		11	203.818	9.369	4.60	153.000	255.000		
2022-524	8 3 ST	84 KX21,300		20	204.750	12.247	5.98	154.000	256.000		
2022-524	9 3 D	50 COULT.JT,M		11	265.364	11.138	4.20	199.000	332.000		
2022-524	9 3 D	68 COULTERAcT		19	267.211	10.273	3.84	200.000	334.000		
2022-524	10 DxH	94 BC DXH 500		38	260.351	14.900	5.72	195.000	325.000		
553 PLATELET COUNT		CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2022-525	1 SYSMEX CBC	75 SYSMEX XT		10	57.100	5.127	8.98	43.000	71.000		
2022-525	1 SYSMEX CBC	79 SYSMEX XS		145	54.538	3.373	6.19	41.000	68.000		
2022-525	1 SYSMEX CBC	87 SYSMEX XN		45	49.886	2.648	5.31	37.000	62.000		
2022-525	1 SYSMEX CBC	98 SYSMEX 350		74	49.973	3.067	6.14	37.000	62.000		
2022-525	2 ACT5 PENTR	73 COULTER AC		129	68.664	4.856	7.07	51.000	86.000		
2022-525	2 ACT5 PENTR	78 ABX PENTRA		28	71.071	4.480	6.30	53.000	89.000		
2022-525	3 ADVIA 120	64 ADVIA-120		17	60.235	5.253	8.72	45.000	75.000		
2022-525	4 AB- CELL-D	63 ABBOTT C-D		118	86.195	5.086	5.90	65.000	108.000		
2022-525	5 BECTON D	83 B.C600,800		58	85.121	2.633	3.09	64.000	106.000		
2022-525	6 MR Mindray	91 BC-5390		48	51.383	2.480	4.83	39.000	64.000		
2022-525	8 3 ST	31 ABBOTT C-D		37	64.222	5.287	8.23	48.000	80.000		
2022-525	8 3 ST	39 SYSMEX K-		11	64.000	3.908	6.11	48.000	80.000		
2022-525	8 3 ST	84 KX21,300		20	62.600	3.800	6.07	47.000	78.000		
2022-525	9 3 D	50 COULT.JT,M		11	74.000	2.000	2.70	56.000	93.000		
2022-525	9 3 D	68 COULTERAcT		19	73.158	3.773	5.16	55.000	91.000		
2022-525	10 DxH	94 BC DXH 500		38	83.447	6.090	7.30	63.000	104.000		

Participant Summary

MONTH 6 OF YEAR 2022

SPEC: 20 HEMATOLOGY SUB: 75 BODY FLUID GRP: 145 BODY FLUID CELL COU.

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
159	BF RED CELL COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
	2022-561				46	0.867	1.147	132.34	0	4.000
	2022-562				46	1033.696	114.291	11.06	691.000	1377.000
	2022-563				46	0.609	0.920	151.19	0	3.000
	2022-564				46	0.783	1.020	130.29	0	4.000
	2022-565				46	1068.356	102.908	9.63	760.000	1377.000
160	BF WHITE CELL COUNT									
	2022-561				45	4.667	2.033	43.57	0	11.000
	2022-562				45	278.133	32.963	11.85	179.000	377.000
	2022-563				45	4.822	1.767	36.65	0.000	10.000
	2022-564				45	4.822	1.841	38.18	0	10.000
	2022-565				45	279.533	39.715	14.21	160.000	399.000

Participant Summary
MONTH 6 OF YEAR 2022

SPE: 30 IMMUNOHEMATOLOGY		SUB: 80 ABO-RH				GRP: 150 ABO-RH							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
083 ABO GROUP													
2022-571				001 003	001 003		002 - A1	84	2	84	100		
2022-571				001 003	001 003		001 - A	84	82	84	100		
2022-572				001 003	001 003		002 - A1	84	2	84	100		
2022-572				001 003	001 003		001 - A	84	82	84	100		
2022-573				004 004	004 004		004 - B	84	84	84	100		
2022-574				008 008	008 008		008 - O	84	84	84	100		
2022-575				008 008	008 008		008 - O	84	84	84	100		
126 RH TYPE													
2022-571				001 003	001 003		001 - Rh+	84	84	84	100		
2022-572				003 004	003 004		003 - Rh-Du np	84	11	84	100		
2022-572				003 004	003 004		004 - Rh-	84	73	84	100		
2022-573				001 003	001 003		001 - Rh+	84	84	84	100		
2022-574				001 003	001 003		001 - Rh+	84	84	84	100		
2022-575				003 004	003 004		003 - Rh-Du np	84	11	84	100		
2022-575				003 004	003 004		004 - Rh-	84	73	84	100		

Participant Summary

MONTH 6 OF YEAR 2022

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 160 Indirect COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
084 INDIRECT COOMBS											
2022-581				001 001	001 001		001 - NEGATIVE	67	67	67	100
2022-582				002 002	002 002		002 - POSITIVE	67	67	67	100
2022-583				001 001	001 001		001 - NEGATIVE	67	67	67	100
2022-584				002 002	002 002		002 - POSITIVE	67	67	67	100
2022-585				001 001	001 001		001 - NEGATIVE	67	67	67	100
SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2022-291	001 Poly AHG	001 Gel			002 004		002 - 2+	14	1	14	100
2022-291	001 Poly AHG	001 Gel			002 004		004 - 4+	14	7	14	100
2022-291	001 Poly AHG	001 Gel			002 004		003 - 3+	14	6	14	100
2022-291	001 Poly AHG	002 Tubo		002 004	002 004		003 - 3+	31	2	31	100
2022-291	001 Poly AHG	002 Tubo		002 004	002 004		002 - 2+	31	27	31	100
2022-291	001 Poly AHG	002 Tubo		002 004	002 004		004 - 4+	31	2	31	100
2022-291	002 MnoAnt-IgG	001 Gel			002 004		003 - 3+	10	4	10	100
2022-291	002 MnoAnt-IgG	001 Gel			002 004		004 - 4+	10	4	10	100
2022-291	002 MnoAnt-IgG	001 Gel			002 004		002 - 2+	10	2	10	100
2022-291	002 MnoAnt-IgG	002 Tubo		002 004	002 004		002 - 2+	16	15	16	100
2022-291	002 MnoAnt-IgG	002 Tubo		002 004	002 004		003 - 3+	16	1	16	100

Participant Summary
MONTH 6 OF YEAR 2022

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2022-292	001 Poly AHG	001 Gel			002 004		003 - 3+	14	6	14	100
2022-292	001 Poly AHG	001 Gel			002 004		004 - 4+	14	7	14	100
2022-292	001 Poly AHG	001 Gel			002 004		002 - 2+	14	1	14	100
2022-292	001 Poly AHG	002 Tubo		002 004	002 004		002 - 2+	31	27	31	100
2022-292	001 Poly AHG	002 Tubo		002 004	002 004		004 - 4+	31	1	31	100
2022-292	001 Poly AHG	002 Tubo		002 004	002 004		003 - 3+	31	3	31	100
2022-292	002 MnoAnt-IgG	001 Gel			002 004		004 - 4+	10	4	10	100
2022-292	002 MnoAnt-IgG	001 Gel			002 004		003 - 3+	10	4	10	100
2022-292	002 MnoAnt-IgG	001 Gel			002 004		002 - 2+	10	2	10	100
2022-292	002 MnoAnt-IgG	002 Tubo		002 004	002 004		002 - 2+	16	16	16	100
2022-293	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	14	14	14	100
2022-293	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	31	31	31	100
2022-293	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	11	11	11	100
2022-293	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	16	16	16	100
2022-294	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	14	14	14	100
2022-294	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	31	31	31	100
2022-294	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	11	11	11	100
2022-294	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	16	16	16	100
2022-295	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	14	14	14	100
2022-295	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	31	31	31	100
2022-295	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	11	11	11	100
2022-295	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	16	16	16	100

Participant Summary

MONTH 6 OF YEAR 2022

SPE: 30 IMMUNOHEMATOLOGY												SUB: 100 COMPATIBILITY TESTING												GRP: 170 COMPATIBILITY TEST.											
TEST	LEVEL 1		LEVEL 2		LEVEL 3		PART		REFEREE		COMMER		REPORTED		PART		# LABS		# "SF"		Score														
SAMPLE	RESULT CODE		RESULT CODE		RESULT CODE		LOW/HIGH		LOW/HIGH		LOW/HIGH		VALUE		LABS		ANSW		LABS																
085 COMPATIBIL. TESTING																																			
2022-591							001	001	001	001				001 - COMPATIBLE	40	39	39			100															
2022-591							001	001	001	001				002 - INCOMPATIB	40	1	39			0															
2022-592							001	001	001	001				001 - COMPATIBLE	40	40	40			100															
2022-593							001	001	001	001				001 - COMPATIBLE	40	39	39			100															
2022-593							001	001	001	001				002 - INCOMPATIB	40	1	39			0															
2022-594							001	001	001	001				001 - COMPATIBLE	40	40	40			100															
2022-595							002	002	002	002				002 - INCOMPATIB	40	40	40			100															